1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. J Clin 67: 7.
2. Benesova M, Bauder-Wust U, Schafer M, (2016) Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J. Med. Chem. 59: 1761.
3. Osborne J, Deh K, Anand A, Bander N, Tagawa S (2013) Prostate specific membrane antigen-based diagnostics in Prostate cancer: A comprehensive perspective. Page: 448, Ed. Tewari A. Springer.
4. Wirtz M, Schmidt A, Schottelius M, Robu S, Gunter T, et al. (2018) Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity EJNMMI Res 8: 84.
5. Ceci F, Fanti S (2019) PSMA-PET/CT imaging in prostate cancer: why and when. Clin. Transl. Imaging 7: 377.
6. Kim Y, Kim Y (2018) Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer. Clin. Nucl. Med. 43: 728.
7. Cardinale J, Schäfer M, Beneˇsová M (2017) Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J. Nucl. Med. 58: 425.
8. Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, et al. (2015) Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med 56: 914.
9. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, et al. (2015) 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 42: 987.
10. Khreish F, Ebert N, Ries M, et al. (2020) 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience” Eur. J. Nucl. Med. Mol. Imaging 47: 721.
11. Cui C, Hanyu M, Haton A (2017) Synthesis and evaluation of [64Cu] PSMA-617 targeted for prostate- specific membrane antigen in prostate cancer. Am. J. Nucl. Med. Mol. Imaging 7: 40.
12. Liu C, Liu T, Zhang N (2018) 68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 45: 1852.
13. Eiber M, Fendler W, Rowe S (2017) Prostate-specific membrane antigen ligands for imaging and therapy” J Nucl Med. 58: 67S.
14. Weineisen M, Schottelius M, Simecek J (2015) 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56: 1169.
15. Hofman MS, Violet J, Hicks RJ (2018) [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (LuPSMA Trial): A Single-Centre, Single-Arm, Phase 2 Study. Lancet Oncol. 19:825.
16. Low P (2021) “177Lu-PSMA-617”.
17. Dash A, Pillai MRA, Knapp FF (2015) Production of 177Lu for targeted radionuclide therapy: available options. Nucl. Med. Mol. Imaging 49: 85.
18. Emmett L, Willowson K, Violet J, Shin J (2017) Lutetium-177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J. Med. Radiat. Sci. 64: 52.
19. Pilaniya K, Chandrawanshi HK, Pilaniya U, Manchandani P, Jain P, et al. (2010) Recent trends in the impurity profile of pharmaceuticals. J Adv Pharm Technol Res 1: 302.
20. “Mammalian liver microsomes” guidelines for use, TF000017 Rev 1.0. Issued by BD Biosciences.
21. Kaplan MM, Utiger RD (1978) Iodothyronine metabolism in rat liver homogenates. J Clin Invest 61: 459.
22. Stringer JL (2017) Chapter 5: Drug Metabolism and Renal Elimination in Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class, 5th ed. McGraw Hil.
23. BD GentestTM, Tissue Fractions, Reagents for Drug Metabolism catalog.